Development of targeted therapy and immunotherapy for treatment of small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer

Published:2018-05-14 Issue:7 Volume:48 Page:603-608
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Saito Motonobu¹²³,Shiraishi Kouya¹,Goto Akiteru⁴,Suzuki Hiroyuki³,Kohno Takashi¹,Kono Koji²

Affiliation:

1. Division of Genome Biology, National Cancer Center Research Institute, Tokyo

2. Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine

3. Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima

4. Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University, Akita, Japan

Funder

JSPS KAKENHI

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/48/7/603/25099620/hyy068.pdf

Reference44 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

2. Unravelling the biology of SCLC: implications for therapy;Sabari;Nat Rev Clin Oncol,2017

3. Results of recent Japanese clinical trials in lung cancer;Ohe;Clin Lung Cancer,2002

4. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124;Lara;J Clin Oncol.,2009

5. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer;Peifer;Nat Genet,2012

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment-related Adverse Events, Including Fatal Toxicities, in Patients With Extensive-stage Small-cell Lung Cancer Receiving Adjuvant Programmed Cell Death 1/Programmed Cell Death Ligand 1 Inhibitors: A Meta-analysis and Trial Sequential Analysis of Randomized Controlled Trials;Clinical Oncology;2024-10

2. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis;Frontiers in Immunology;2024-04-17

3. The inhibitory effect of apatinib on different small cell lung cancer cells and in lung cancer‐bearing mice and patients;The Clinical Respiratory Journal;2024-02

4. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways;International Immunopharmacology;2023-09

5. Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance;Acta Biochimica et Biophysica Sinica;2023-05-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3